MyAmyloidosisTeam

Yes, Amvuttra has been used to treat hATTR amyloidosis since its FDA approval in 2022. While it's newer than some other treatments, early clinical trial results have been encouraging, showing similar or sometimes improved outcomes compared to alternatives.

The medication is given as a subcutaneous injection (shot under the Show Full Answer

Yes, Amvuttra has been used to treat hATTR amyloidosis since its FDA approval in 2022. While it's newer than some other treatments, early clinical trial results have been encouraging, showing similar or sometimes improved outcomes compared to alternatives.

The medication is given as a subcutaneous injection (shot under the skin) and can sometimes be administered at home by a trained caregiver or nurse. This makes it more convenient for many patients compared to treatments requiring clinic visits. Some key benefits of Amvuttra include:
• Less frequent dosing schedule
• No requirement for premedications
• Lower likelihood of infusion-related reactions
• Option for home administration in some cases
• Typically only causes mild injection site reactions when side effects occur

Your doctor can help determine if Amvuttra might be right for you based on your specific situation, including factors like your lifestyle, other health conditions, and insurance coverage.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Onpattro vs. Amvuttra for hATTR Amyloidosis: 7 Differences